基于微针的透皮输送系统用于代谢性骨疾病:进展,挑战和未来的前景
Xingwen Xie1,2, Xianli Zheng1, Dingpeng Li3
1Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China.
Frontiers in bioengineering and biotechnology
|March 13, 2026
概括
微针 (MN) 系统为代谢性骨病 (MBDs) 提供了一种新的透皮方法. 这项技术提高了药物输送和患者的坚持,克服了传统口服和注射疗法的局限性.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢性骨病 (MBD),如骨质疏松症和恶心,由于慢性管理和全身疗法的局限性,造成了治疗挑战.
- 口服药物具有较差的生物可用性和胃肠道不耐受性,而注射生物药物则面临坚持问题.
- 微针 (MN) 系统为克服这些输送障碍提供了一个有前途的透皮替代方案.
研究的目的:
- 为治疗代谢性骨病 (MBD) 提供微针 (MN) 技术的全面审查.
- 分析MNs演变为针对性骨疗法的智能平台.
- 总结临床前的进展,并讨论基于MN的MBD治疗的未来方向.
主要方法:
- 审查微针分类,材料和通过皮肤递送的优势.
- 分析智能 MN 设计,其中包括骨准配体和刺激响应系统.
- 关于MBD的MN应用的临床前研究总结,重点是药理动力学和疗效.
主要成果:
- 多核瘤有效地绕过角层,可提供无痛的药物输送.
- 智能MN可以通过有针对性的输送和受控释放精确调节骨微环境.
- 临床前研究表明,基于MN的MBD治疗的药理动力学概况和治疗疗效得到改善.
结论:
- 微针技术为管理代谢性骨疾病提供了一种变革性的方法.
- 进一步研究制造,安全和临床翻译对于广泛采用至关重要.
- 结合传感和适应性治疗的下一代MN系统承诺个性化骨健康管理.
相关概念视频
01:18Transdermal Drug Delivery Systems
87
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
87
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
85
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
85
01:26Oral Drug Delivery Systems: Continuous-Release Systems
135
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135
01:24Modified-Release Drug Delivery Systems: Site-Targeted
70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
01:27Drug Delivery Systems: Different Types
163
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
163
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
73
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
73